Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 91, Issue 3, Pages 529-534Publisher
WILEY
DOI: 10.1038/clpt.2011.300
Keywords
-
Categories
Ask authors/readers for more resources
The ability to predict clinical safety based on chemical structures is becoming an increasingly important part of regulatory decision making. (Quantitative) structure-activity relationship ((Q)SAR) models are currently used to evaluate late-arising safety concerns and possible nonclinical effects of a drug and its related compounds when adequate safety data are absent or equivocal. Regulatory use will likely increase with the standardization of analytical approaches, more complete and reliable data collection methods, and a better understanding of toxicity mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available